ADEF
CLBT icon

ABS Direct Equity Fund’s Cellebrite CLBT Stock Holding History

ABS Direct Equity Fund’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-250,000
Closed -$3.44M – 123
2026
Q1 		$3.44M Buy
+250,000
New +$3.77M 2.63% 12

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

ABS Direct Equity Fund's CLBT Position: Q2 2026 in Review

ABS Direct Equity Fund sold out of Cellebrite (CLBT) in Q2 2026, closing a stake of 250,000 shares — an estimated $3.44M sold.

ABS Direct Equity Fund first reported a position in CLBT in Q1 2026 and held it in 1 quarter. The position peaked at $3.44M in Q1 2026. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • ABS Direct Equity Fund reported no remaining Cellebrite position as of Q2 2026 after selling out during the quarter.
  • ABS Direct Equity Fund sold 250,000 Cellebrite shares in Q2 2026, an estimated $3.44M.
  • ABS Direct Equity Fund first reported a position in Cellebrite in Q1 2026 and held it in 1 quarter.
  • ABS Direct Equity Fund's Cellebrite position peaked at $3.44M in Q1 2026.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on ABS Direct Equity Fund's 13F filing for Q2 2026, filed 13 Aug 2026.